YL217 will enter phase 1 before Sotio's similarly acting rival, licensed from Biocytogen.
ApexOnco Front Page
Recent articles
While Sutro shows why it’s shelved luvelta-T.
The small cap biotech Instil Bio tries to follow in Summit’s slipstream.
Patients' expression of CEACAM5 might hold the key to activity after all.
Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.
The fortunes of RLY-2608 reverse, and a pivotal study will follow.
Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.
The group is going beyond EGFR exon 20 insertions, but still has work to do to justify its valuation.